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blood pressure. These findings argue against a specific role forInduction of albuminuria in mice: Synergistic effect of two
angiotensin II in this model.monoclonal antibodies directed to different domains of amino-
Conclusions. The combined injection of two mAbs directedpeptidase A.
against different domains of aminopeptidase A induces a mas-Background. Aminopeptidase A is an enzyme that is present
sive albuminuria in mice, which is not merely dependent onon podocytes and is involved in the degradation of angiotensin
angiotensin II. We hypothesize that the direct binding of mAbsII. In previous studies in mice, we administered single mono-
to at least two pathogenic domains on aminopeptidase A trig-clonal antibodies directed against aminopeptidase A. We ob-
gers the podocyte to release mediators that are involved in theserved that only monoclonal antibodies that inhibited amino-
observed albuminuria.peptidase A enzyme activity caused albuminuria.
Methods. In this study, the effects of the combined injections
of two monoclonal anti-aminopeptidase A antibodies (mAbs)
were studied, using a combination of anti-aminopeptidase A
Glomerular visceral epithelial cells on the outer sidemAbs that were directed against two different domains in-
of the glomerular capillary wall, also called podocytes,volved in the aminopeptidase A enzyme activity (ASD-3 or
ASD-37) and an anti-aminopeptidase A mAb not related to have an instrumental role in the maintenance of the
the enzyme active site (ASD-41). structural integrity of the capillary wall, as well as the
Results. An injection of the combinations ASD-3/37 (total functioning of the glomerular filtration barrier. Recent4 mg, 1:1 ratio) and ASD-37/41 (total 4 mg, 1:1 ratio) in doses
evidence suggests that podocytes may be actively in-that do not cause albuminuria when given alone (4 mg) induced
volved in pathological processes of the glomerulus [1].massive albuminuria at day 1 after injection. The combination
ASD-3/41 had no effect. This albuminuria was not dependent Studies in Heymann nephritis (HN) have shown that
on systemic immune mediators of inflammation and could not podocytic antigens can serve as targets for circulating
merely be related to a blockade of aminopeptidase A enzyme antibodies [2–5]. A few new models of antibody-medi-activity. However, a correlation was observed between the
ated activation or injury of podocytes, characterized byinduction of albuminuria and the aggregation of the mAbs
overt proteinuria, have been published. Examples in-injected and aminopeptidase A on the podocytes. An injection
of the combinations ASD-3/37 or ASD-37/41 did not cause clude the nephropathy occurring in graft-versus-host
an increase in systemic blood pressure. The treatment with a mice and the glomerulopathy induced by the monoclonal
combination of enalapril and losartan lowered blood pressure antibody (mAb) 5-1-6 [6–9].(53 6 10 vs. 90 6 3 mm Hg in untreated mice) and reduced
Recently, we have described a mouse model of podo-the acute albuminuria by 55% (11,145 6 864 vs. 24,517 6 2448
cytic activation or injury that could be induced by a singlemg albumin/18 hr in untreated mice). However, similar effects
were observed using triple therapy. Therefore, the reduction intravenous injection of a relatively large amount of a
of albuminuria by the combined treatment of enalapril/losartan mAb against mouse aminopeptidase A (APA), a metal-
seems to be the consequence of the reduction in the systemic
loprotease present in the mouse kidney on podocytes,
brush borders of proximal tubular epithelial cells, granu-
lar juxtaglomerular cells, endothelial cells of the peritu-Key words: membranous glomerulonephritis, renin-angiotensin sys-
tem, angiotensin II, podocyte, glomerular filtration barrier, proteinuria. bular capillaries, and smooth muscle cells of arteries [10,
11]. APA (EC 3.4.11.7) hydrolyzes N-terminal aspartyl
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and glutamyl residues from peptides [12]. One of theand in revised form October 30, 1998
Accepted for publication November 2, 1998 best known functions of APA is its degrading effect on
angiotensin II (Ang II), the most active component of the 1999 by the International Society of Nephrology
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Table 2. Immunofluorescence blocking study on frozen kidneyTable 1. Characteristics of three monoclonal antibodies (mAbs)
against mouse aminopeptidase Aa sections of a normal BALB/c mouse with anti-APA
monoclonal antibodies (mAbs)
IgG FEAc Enzyme inhibition
mAb subclass IEPb % activity in vivod Albuminuria mAb code ASD-3 ASD-37 ASD-41
ASD-3Biot 1 2 2ASD-3 IgG1 6.7 8 1 1
ASD-37 IgG2a 6.5 18 1 1 ASD-37Biot 2 1 2
ASD-41Biot 2 2 1ASD-41 IgG2a 6.8 93 2 2
Unlabeled anti-aminopeptidase A (APA) mAbs block (1) or do not blocka According to reference [10]
b Isoelectric focusing: the isoelectric point (IEP) of each mAb is given as the (2) the binding of biotinylated anti-APA mAbs (ASD-Biot).
mean of the three glycosylated isoforms
c Fluorimetric enzyme assay: residual APA activity of a renal brush border
enriched suspension after incubation with 100 mg mAb derived from the superna-
tant of cultured hybridomas
d Inhibition of renal enzyme activity measured by enzyme histochemistry (see METHODS
Methods section) after i.v. injection of 16 mg of each mAb
Characteristics of anti-aminopeptidase A
monoclonal antibodies
Monoclonal antibodies. The three mAbs against APA
renin-angiotensin system [13, 14]. Only some antibodies used in this study (ASD-3, ASD-37, and ASD-41) have
were able to induce an acute albuminuria. This acute been propagated as ascites in BALB/c nu/nu mice and
albuminuria was not dependent on systemic mediators, purified by ammonium sulfate precipitation as described
such as inflammatory cells, complement, or the coagula- (Table 1) [10, 11, 15]. The titers of the three mAb prepa-
tion system. Additional studies suggested that Ang II rations were comparable, as tested by indirect immuno-
could play an important role in the induction of albumin- fluorescence (IF).
uria. First, albuminuria could only be induced by mAbs Fluorometric enzyme assay. To determine the effects
that were able to block APA enzyme activity, whereas of the anti-APA mAbs on the APA enzyme activity in
non-enzyme–inhibiting mAbs were ineffective. The treat- vitro, a mouse renal brush border preparation solubilized
ment of mice with the angiotensin-converting enzyme in 1% sodium deoxycholate was preincubated with each
(ACE) inhibitor enalapril or the angiotensin II type 1 of the anti-APA mAbs, and subsequently, the APA en-
(AT1)-specific Ang II receptor antagonist losartan and zyme activity was determined with a specific substrate
measurements of renal APA mRNA expression as an (0.6 mm l-glutamic acid-a-7-amido-4-methyl coumarin;
indicator of the local Ang II levels provided further evi- Bachem, Bubendorf, Switzerland) as described [10, 17].
dence that the acute albuminuria after a single injection The enzyme activities are expressed as percentages of the
of an enzyme-inhibiting anti-APA mAb might be medi- activity present in the control brush border suspension.
ated by the action of Ang II on systemic and/or renal Indirect inhibition immunofluorescence on frozen mouse
hemodynamics [15]. kidney sections. The selection of the three mAbs used
Recent studies in HN have suggested that multiple in this study from eight mAbs [10] was based on their
specific domains present on the podocytic antigens mega- specificity for three different domains on APA. This was
lin and the receptor-associated protein are involved in examined by an indirect immunofluorescence (IF) assay
the development of the subepithelial immune complexes on normal mouse kidney sections in order to see whether
[4, 16]. In this study, we have examined the effects of anti-APA mAbs were able to prevent each other’s bind-
the combined administration of two anti-APA mAbs, ing to APA (Table 2). For this inhibition assay, all three
directed against different domains of APA. Our study anti-APA mAbs were biotinylated with N-hydroxysuc-
shows that the combined injection of two anti-APA cinimidobiotin (Sigma, St. Louis, MO, USA). Two-micro-
mAbs, in doses that do not cause albuminuria when meter thick frozen mouse kidney sections fixed in acetone
given alone, induces a massive albuminuria. This albu- were preincubated with an avidin/biotin blocking kit ac-
minuria is also observed when using a mAb in the combi- cording to the instructions of the manufacturer (Vector,
nation that does not inhibit APA enzyme activity. This Burlingame, CA, USA) to block endogenous biotin.
albuminuria is not merely related to a decreased enzyme After rinsing in phosphate-buffered saline (PBS), the
activity or an increase of Ang II activity, but rather, sections were first incubated with an unlabeled anti-APA
seems correlated to the aggregation of the injected mAbs mAb, diluted 1:100 in PBS/1% bovine serum albumin
and APA on the cell membranes. We hypothesize that for one hour at room temperature and were rinsed for
podocytic mediators are involved in the induction of 10 minutes in PBS. Next, the sections were incubated
albuminuria in this model. Further studies on the role with one of the biotinylated anti-APA mAbs, diluted
of specific domains involved in the induction of acute 1:10 in PBS/1% bovine serum albumin for one hour at
albuminuria and the events resulting from the binding room temperature, followed by a wash for 10 minutes
of the antibodies might add to our understanding of in PBS. Binding of the biotinylated anti-APA mAb was
visualized by the tetramethylisothiocyanate-labeled strep-podocyte activation and glomerulonephritis.
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Table 3. Effect of different concentrations of combinations of two In an additional experiment, mice were injected i.v. with
anti-APA mAbs administered to BALB/c mice
different doses, ranging from a total dose of 0.125 to 4.0
Glomerular Glomerular mg of the combinations ASD-3/37 and ASD-37/41 (1:1
Dose Albuminuriaa bindingb enzyme weight ratio; Table 3). The Ig concentration of themAb code mg N lg/18 hr (IF) activityc
batches of mAbs was determined by radial immunodiffu-
ASD-3/37 0.125 3 104633 111H 1111
sion [21]. Albuminuria, as a sign of glomerular protein0.25 3 174632 111 111
0.5 3 440647 111 111 leakage, was measured in 18-hour urine samples col-
1.0 3 565614 1111 11 lected at 6 to 24 hours after an injection of the mAbs
2.0 3 10,66762699 1111 1
by radial immunodiffusion as described [10, 21, 22].4.0 3 12,18762847 1111G 6
Pathological albuminuria was defined as a value greater
ASD-37/41 0.125 3 6868 111H 1111
than the normal mean plus two sd (more than 100 mg0.25 3 82618 111 111
0.5 3 3466103 111 111 albumin/18 hr) [22]. Kidney fragments were prepared for
1.0 3 805262291 1111 11 light microscopy, IF, electron microscopy, and enzyme
2.0 3 26,57265294 1111 11
histochemistry.4.0 4 30,07961669 1111G 1/11
Effects of angiotensin II blockade on blood pressurea Albumin excretion determined by radial immunodiffusion on 18 h urine
samples at day one after i.v. injection of the different concentrations of the and albuminuria. To examine if Ang II could be involved
combinations of two mAbs. Values are given as mean 6 sem in the induction of albuminuria, we studied the effect ofb The binding of the different concentrations of injected anti-APA mAb combi-
nations at day one after i.v. injection of the mAb combinations was evaluated the combined treatment with the ACE inhibitor enala-
by direct IF. The binding pattern gradually changed from a homogenous (H) pril and the AT1 receptor blocker losartan on the acutebinding at the lowest dose to a granular (G) binding at the highest dose.
c Residual renal APA enzyme activity as measured by enzyme histochemistry albuminuria and systemic blood pressure in BALB/c
(see Methods section) at one day after i.v. injection of the different concentrations mice treated with the combination ASD-37/41. Enalaprilof the anti-APA mAb combinations
and losartan were given in combination to ensure a maxi-
mally effective treatment. Two groups of mice (A and
B, N 5 7 each) received active treatment. Enalapril and
tavidin procedure [18]. The sections were embedded in losartan were added to the drinking water (each 100
aquamount (BDH, Poole, UK) and examined in a fluo- mg/liter), and in addition, each mouse received 0.5 mg
rescence microscope equipped with a Ploemopak epiil- enalapril and 0.5 mg losartan by gavage every 12 hours
lumination (Leitz, Letzlar, Germany). [15]. A control group (C, N 5 7) was treated with normal
Immunoprecipitation. A solid-phase immunoprecipi- drinking water by gavage every 12 hours. This treatment
tation on a 125I-radiolabeled suspension of renal brush
started one day before injection of the mAbs and wasborder proteins solubilized by 1% sodium deoxycholate
continued during the rest of the experiment. At 24 hourswas carried out for the three anti-APA mAbs as de-
after the enalapril/losartan treatment was started, twoscribed before [10, 11].
groups (B and C) were injected intravenously with aWestern blotting. Sodium deoxycholate (1%)-solubi-
total dose of 2 mg of the combination ASD-37/41 (1:1lized renal brush border proteins were separated on a
ratio), whereas one group (A) was intravenously injected7.5% sodium dodecyl sulfate-polyacrylamide gel electro-
with a similar volume of saline. Six hours after the intra-phoresis and electrophoretically transferred to a nitro-
venous injections, mice were placed in a metabolic cage,cellulose membrane, as described before [19, 20]. The
and urine was collected during an 18-hour period for thenitrocellulose membranes were blocked with low-fat
determination of the albuminuria as described [10, 21,milk powder and incubated with one of the anti-APA
22]. Twenty-four hours after the mAbs or saline weremAbs overnight, followed by a peroxidase-conjugated
injected, that is, 12 hours after the administration ofrabbit anti-rat IgG (Seralab, Harlan, UK) for two hours
the last dose of the antihypertensive drugs, the systemicat room temperature. Next the membranes were devel-
blood pressure was measured in each group. In addition,oped with the chemiluminescence blotting substrate kit
the blood pressures of two groups of five male BALB/caccording to the instructions of the manufacturer (Boeh-
mice were measured at day 1 after a single intravenousringer-Mannheim, Mannheim, Germany) and were ex-
injection of 2 mg ASD-3/37 (1 mg ASD-3 1 1 mg ASD-posed to preflashed x-ray films (Kodak X-omat; Kodak,
37) or the same volume of saline to compare its effectsRochester, NY, USA) for 40 seconds.
on the systemic blood pressure with the combination of
Animal experiments 2 mg ASD-37/41. To evaluate whether the effects of Ang
II blockade on the albuminuria are rather specific orInjection of single mAbs or combinations of two mAbs.
merely related to nonspecific blood pressure reduction,Six- to eight-week-old male BALB/c mice were injected
similar experiments were conducted in which the miceintravenously with a total dose of 4 mg of the combina-
were treated with “triple therapy.” In these studies, thetions of two anti-APA mAbs, that is, ASD-3/37, ASD-
protocols mentioned earlier here were used, but the ena-3/41, and ASD-37/41 (1:1 weight ratio) or with 4 mg of
either ASD-3, ASD-37, or ASD-41 alone (Tables 1 and 3). lapril/losartan treatment was replaced by an intraperito-
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neal injection of 0.25 mg atenolol (Sigma), 0.25 mg hydro- sections were examined in an electron microscope (JEOL
1200 EX2; JEOL, Tokyo, Japan).chlorothiazide (Sigma), and 1.0 mg hydralasin (Sigma)
every 12 hours in the groups A and B (N 5 7 each) or Examination of invading inflammatory cells. To deter-
mine whether or not the injection of the anti-APA anti-the same volume of saline every 12 hours in group C
(N 5 7). After these procedures, kidney fragments were bodies is accompanied by an influx of inflammatory cells
into the glomeruli, kidney sections were examined by lightprepared for light microscopy, IF, electron microscopy,
and enzyme histochemistry. microscopy in mice injected with 4 mg ASD-37/41 (N 5 3)
and compared with control kidney sections from normalSystemic blood pressure measurements. For systemic
blood pressure measurements, mice were anesthetized mice (N 5 5). The numbers of polymorphonuclear gran-
ulocytes (PMN) and mononuclear cells were counted inwith 0.8% halothane (Zeneca, Macclesfield, UK) in com-
bination with 400 cc O2/min. After anesthetization, the at least 40 glomeruli and expressed as the mean number
per glomerular cross section. In addition, the glomerularabdomen was opened, and a 19 mm, 24-gauge neoflon
catheter (BOC Ohmeda, Helsingborg, Sweden) was in- influx of inflammatory cells was examined in more detail
by IF specific for PMN, T cells, and macrophages, respec-serted in the arteria femoralis just beneath the aortic
bifurcation. The catheter was connected to a pressure tively. The glomerular PMN were determined in 4 mm
sections using the rat anti-mouse PMN mAb NIMP-R14transducer (Hewlett Packard, Palo Alto, CA, USA), and
after a three- to five-minute stabilization period, the mean (IgG2b subclass) [23, 24] as the first antibody and an
FITC-labeled, subclass-specific sheep IgG 2b anti-ratarterial pressure was monitored during a 10-minute pe-
riod. After the measurement, the mice were killed by IgG (Serotec) as the secondary antibody. The number
of glomerular T cells was determined by incubating acervical dislocation.
4 mm cryostat section with a R-phycoerythrin–labeled
Histology hamster anti-mouse CD3 mAb (Pharmingen, San Diego,
CA, USA). The numbers of PMN and T cells wereLight microscopy, immunofluorescence, and electron
microscopy. For light microscopy, kidney fragments were counted in at least 40 glomeruli and were expressed as
the mean number per glomerular cross section. Unfortu-fixed in Bouin’s solution and embedded in paraplast (Am-
stelstad, Amsterdam, The Netherlands). Two microme- nately, we were not able to determine the number of
glomerular macrophages by IF, due to a cross reactivityter sections were stained with periodic acid Schiff and
methenamine silver. For IF, kidney fragments were snap of the secondary FITC-labeled antibody to both FA/11
(the only available rat anti-mouse mAb that detects allfrozen in liquid nitrogen, and 2 mm cryostat sections were
stained with fluorescein isothiocyanate (FITC)-labeled subsets of mouse macrophages [25, 26]) and the injected
anti-APA mAbs, which both are of the IgG2a subclass.sheep antimouse Ig (Cappel Laboratories, West Chester,
PA, USA), goat antimouse C3, and rabbit anti-mouse Enzyme histochemistry. The enzyme activity of APA
in the mouse kidneys was visualized by enzyme histochem-fibrinogen (both from Nordic, Tilburg, The Netherlands).
The binding of the injected anti-APA mAb was exam- istry according to Lojda and Gossrau [27] with the APA-
specific substrate L-glutamic acid-4-methoxy-b-naph-ined by direct IF with a FITC-labeled rabbit anti-rat IgG
(Dako, Copenhagen, Denmark) as described before [10]. tylamide (Bachem, Bubendorf, Switzerland) as described
before [11, 15]. The intensity of the developed color wasThe expression of APA was examined by indirect IF
with an anti-APA mAb (ASD-38, subclass IgG2b) that recorded semiquantitatively on a scale from 0 to 41.
was of a different subclass and did not affect the binding
Statistical analysisof the three mAbs used in this study, followed by an
incubation with a FITC-labeled, subclass-specific sheep For statistical analysis, analysis of variance was used,
and group comparisons were done with the Tukey–anti-rat IgG2b antiserum (Serotec, Oxford, UK). The
sections were examined in a fluorescence microscope Kramer test. P values less than 0.05 were regarded as
significant. All values are expressed as means 6 sem.(Leitz), and the staining intensity was recorded semi-
quantitatively on a scale from 0 to 41 as described earlier
[10]. For electron microscopy, small pieces of cortex were
RESULTS
fixed in 2.5% glutaraldehyde dissolved in 0.1 m sodium
Characteristics of the monoclonal anti-mousecacodylate buffer, pH 7.4, for four hours at 48C, and
aminopeptidase A antibodieswashed in the same buffer. The tissue fragments were
postfixed in cacodylate-buffered 1% OsO4 for one hour, The characteristics of the three mAbs against APA
used in this study, that is, ASD-3, ASD-37, and ASD-41,dehydrated, and embedded in Epon 812 (Merck, Darm-
stadt, Germany). Ultrathin sections were cut on an ul- are summarized in Table 1. In contrast to ASD-41,
ASD-3 and ASD-37 inhibit the APA enzyme activity intratome (LKB Instruments, Bromma, Sweden) and
stained with 4% uranyl acetate for 45 minutes and with vitro and in vivo. The results of the inhibition IF assay
on normal mouse kidney sections indicate that the threelead citrate for two minutes at room temperature. The
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Effects of combined injection of two monoclonal anti-
aminopeptidase A antibodies
In an initial experiment, the effect of the combined
administration of two of the aforementioned mAbs in a
total dose of 4 mg in a 1:1 ratio was measured (Fig. 2).
An injection of the combination of ASD-3 and ASD-37,
both enzyme inhibitors, induced a prominent albumin-
uria at day 1 of 12,187 6 2847 mg/18 hr (N 5 3). The
administration of ASD-37 in combination with the non-
enzyme–inhibiting ASD-41 resulted in an even higher
albuminuria at day 1, that is, 30,079 6 1669 mg/18 hr
(N 5 4), whereas an injection of ASD-3 in combination
with ASD-41 had hardly an effect on the albumin excre-
tion [128 6 12 mg albumin/18 hr (N 5 3); physiological
albuminuria of less than 100 mg/18 hr]. An injection of
4 mg ASD-3, ASD-37, or ASD-41 alone also had little
effect on the albuminuria (207 and 203 mg/18 hr, 77 and
135 mg/18 hr, and 118 and 290 mg/18 hr, respectively;
N 5 2/mAb). By injecting mice with varying amounts
of the combinations ASD-3/37 and ASD-37/41 in a 1:1
ratio, ranging from 0.125 to 4 mg, we could demonstrate
that both combinations induced an acute albuminuria in
a dose-dependent fashion (Table 3).
Effects of antihypertensive therapies on the acute
albuminuria and systemic blood pressure
In a previous study, we found that the acute albumin-
uria induced with a single enzyme-inhibiting anti-APAFig. 1. (A) An autoradiogram of the immunoprecipitation analysis of
a radiolabeled mouse brush border suspension after sodium dodecyl mAb could almost completely be attenuated by treatment
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; 7.5%). In all with the ACE-inhibitor enalapril or the AT1-receptor an-three lanes (ASD-3, ASD-37, and ASD-41), a single band of approxi-
tagonist losartan [15]. From these studies, we concludedmately 140 kDa is seen. (B) A Western blot of a renal brush border
solution separated on a 7.5% SDS-PAGE incubated with ASD-3, that the acute albuminuria after the administration of a
ASD-37, or ASD-41, respectively. In only lane 2 (ASD-37) can a strong single anti-APA mAb might be mediated by the actionband of approximately 140 kDa be seen. It is absent in the other two
of Ang II, the best known substrate of APA, on thelanes. On the left, the molecular weights of the markers are indicated.
glomerular or systemic hemodynamics. Therefore, we
first studied the effect of injection of 2 mg (1:1 ratio) of
the pathogenic combinations ASD-3/37 and ASD-37/41mAbs are directed to different domains on the APA
on the mean arterial pressure. The injection of bothmolecule (Table 2). The fact that each of the mAbs
combinations did not increase the mean arterial bloodcould block its own binding to APA on frozen sections
pressure as compared with control animals injected withconfirmed the validity of this inhibition IF assay. In the
saline [87 6 3 mm Hg (ASD-3/37) and 90 6 3 mm Hgsolid-phase immunoprecipitation procedure, all three
(ASD-37/41) vs. 90 6 1 mm Hg (saline controls); Fig. 3].mAbs ASD-3, ASD-37, and ASD-41 were able to precip-
For studying the effects of the antihypertensive treat-itate the 140 kDa APA protein from a radiolabeled renal
ments on the acute albuminuria and mean arterial pres-suspension (Fig. 1A). In contrast, in the Western blotting
sure, we used the most potent combination, that is, ASD-experiment, only incubation with ASD-37 resulted in a
37/41. The treatment of mice injected with a total dose140 kDa band characteristic for the monomeric APA
of 2 mg (1:1 ratio) ASD-37/41 with a combination ofglycoprotein (Fig. 1B). From these findings, we deduct
enalapril and losartan lowered the mean arterial pressurethat the three mAbs used in this study are directed
(53 6 10 mm Hg vs. 90 6 3 mm Hg in controls; Fig. 3)against three different domains on the APA molecule,
and reduced the acute albuminuria by 55% (11,145 6two of which are related to the enzyme active site (ASD-3
864 mg/18 hr vs. 24,517 6 2448 mg/18 hr in untreatedand ASD-37). Furthermore, the results of the immuno-
mice; Fig. 3). To examine whether the reduction in acuteprecipitation and Western blotting experiments indicate
albuminuria is merely caused by the reduced systemicthat ASD-37 is directed against a linear domain, whereas
ASD-3 and ASD-41 recognize nonlinear domains. blood pressure or specifically related to Ang II blockade,
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Fig. 2. Albuminuria at one day after an intra-
venous injection of 4 mg ASD-3, ASD-37, or
ASD-41 alone or 4 mg (2 mg 1 2 mg) of
the combinations ASD-3/37, ASD-3/41, and
ASD-37/41. Albuminuria is given as the total
amount of albumin in 18-hour urine samples
(mean 6 sem). The glomerular binding and
the glomerular enzyme activity are indicated
beneath each mAb. HHomogenous binding
along the glomerular capillary wall. GGranular
binding along the glomerular capillary wall.
mice injected with 2 mg (1:1 ratio) of ASD-37/41 were these two combinations (Figs. 2 and 4B). An administra-
tion of 4 mg of the combination ASD-3/41 or 4 mg oftreated with a non-Ang II coupled antihypertensive ther-
apy, that is, a triple therapy with a b-blocker, a vasodila- the single mAbs ASD-3, ASD-37, or ASD-41, however,
led to a homogenous binding to the capillary wall andtor, and a diuretic. This triple-therapy treatment lowered
the mean arterial pressure (64 6 5 mm Hg vs. 87 6 3 had no effect on the normal homogenous localization of
APA on the podocytes (Figs. 2 and 4 C, D). In the dose–mm Hg in controls; Fig. 3) and reduced the acute albu-
minuria by 82% (4046 6 1262 mg/18 hr vs. 23,099 6 7901 response studies with the combinations ASD-3/37 and
ASD-37/41, the homogenous binding to the glomerularmg/18 hr in untreated mice; Fig. 3).
capillary wall with the lowest doses gradually changed
Histology into a granular pattern with higher doses (Table 3). In
addition, with increasing doses, we observed binding toBy light microscopy, none of the mice injected with
various amounts of ASD-3/37, ASD-3/41, or ASD-37/41 the endothelial cells of the peritubular capillaries, the
smooth muscle cells of the media of arteries, basolateralor single mAbs showed glomerular abnormalities at day 1.
In particular, neither an influx of PMN or mononuclear sides of the proximal tubular epithelial cells, and occa-
sionally to the brush border of these cells at higher doses,cells nor a proliferation of resident glomerular cells could
be observed. The absence of invading PMN and T cells as reported earlier for the administration of a single mAb
(Fig. 4 A, B) [10, 15]. The treatment with enalapril/could be confirmed by IF. In albuminuric mice, however,
protein casts and vacuolization of the proximal tubular losartan or the triple therapy had no effect on the binding
intensity or distribution of the injected mAbs and theepithelial cells were seen. By IF, mice injected with all
three combinations of mAbs did not demonstrate fibrin expression of APA on the podocytes. By electron micros-
copy (EM), no electron dense deposits were observeddeposits in the glomerular tuft, and there were only small
traces of mouse immunoglobulin and complement in the on the epithelial side of the glomerular basement mem-
brane, that is, the slit pores and below the podocytic footmesangium, a normal finding in this mouse strain. One
day after the injection of the highest dose of the three processes, of mice injected with 4 mg of mAb alone or
in combination. Furthermore, no evidence was found forcombinations or the single mAbs, a difference in the
glomerular binding was observed between the albumin- podocyte detachment in 78 glomerular cross sections of
mice injected with 4 mg ASD-37/41. However, a fusionuric combinations ASD-3/37 and ASD-37/41 on the one
hand and the nonalbuminuric combination ASD-3/41 or of the podocytic foot processes was observed at one day
after injection of 4 mg ASD-37/41 and to a lesser degreethe single mAbs ASD-3, ASD-37, or ASD-41 on the
other hand (Figs. 2 and 4 A, C). An injection of ASD- with 4 mg ASD-3/37 (Fig. 5).
By enzyme histochemistry on frozen kidney sections,3/37 and ASD-37/41 resulted in a fine granular binding
pattern along the glomerular capillary wall (Figs. 2 and we found that a single injection of 4 mg of one of the
mAbs had only little (ASD-3 and ASD-37) or no (ASD-4A). Also, the glomerular APA expression changed from
a homogenous into a granular pattern after injection of 41) inhibiting effect on the glomerular enzyme activity
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Fig. 3. Effect of the administration of the combinations ASD-3/37 and ASD-37/41 (A), and the antihypertensive treatments (B) on the mean
arterial pressure (MAP; left) and the induction of acute albuminuria (right). (A) Administration of 2 mg ASD-3/37 and ASD-37/41 (1:1 weight
ratio), both of which induced massive albuminuria (right), have no effect on MAP compared with the injection of saline (left). (B) Both the
combined enalapril/losartan treatment and the triple therapy reduced the MAP (left) and albuminuria (right) of mice injected with 2 mg ASD-
37/41 (1:1 weight ratio). Both treatments had comparable effects on MAP of mice injected with saline (left). Mice that received water (gavage)
or saline instead of the antihypertensive treatments served as controls. The triple therapy was composed of b-blocker (atenolol), a vasodilator
(hydralazine), and a diuretic (hydrochlorothiazide). In the enalapril/losartan treatment, MAP values are *P , 0.05 and **P , 0.01 vs. control;
albuminuria values are ***P , 0.001 vs. control. With the triple therapy, the MAP value is **P , 0.01 vs. control and albuminuria values are
*P , 0.05 and **P , 0.01 vs. control.
Mentzel et al: Induction of albuminuria in mice1342
Fig. 4. Antibody binding and aminopeptidase A (APA) expression in a mouse kidney at day one after injection of a total dose of 4 mg ASD-
3/37 (A and B; 3600) or a total dose of 4 mg ASD-3/41 (C and D; 31100). An injection of ASD-3/37 resulted in a granular binding of the mAbs
along the glomerular capillary wall (A). The glomerular expression of APA changed from a homogenous into a granular pattern after injection
of ASD-3/37 (B). In contrast, an injection of ASD-3/41 resulted in a homogenous binding along the glomerular capillary wall (C) and, in addition,
did not affect the homogenous expression of APA in glomeruli (D).
(Table 1). In additional experiments, we found that an combination ASD-3/37 almost completely blocked the
glomerular enzyme activity, whereas 4 mg ASD-37/41injection of 8 mg ASD-37 alone almost completely inhib-
ited the enzyme activity, but did not result in an albumin- considerably but not completely inhibited the enzyme
activity (Table 3 and Fig. 6 A, B). Remarkably, the inhibi-uria (84 6 22 mg albumin/18 hr, N 5 3). An injection of
the pathogenic combinations ASD-3/37 and ASD-37/41 tion of glomerular enzyme activity with 4 mg ASD-37/41
(that is, 2 mg ASD-37) was greater than with 4 mg ofdose dependently decreased the glomerular APA activ-
ity (Table 3 and Fig. 6 A, B). Four milligrams of the ASD-37 alone. The administration of 4 mg ASD-3/41 had
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Fig. 5. An electron microscopic picture of a glomerulus of a mouse injected with the combination of 4 mg ASD-37/41. Incomplete fusion of the
foot processes can be seen. In the subepithelial space, particularly the slit pores, of the glomerular basement membrane, no electron dense deposits
are present (331,000). Abbreviations are: Cap, capillary lumen; Pod, podocytes.
only a minor inhibiting effect on the glomerular enzyme merulonephritis accompanied by an acute albuminuria
after a single intravenous injection of a relatively largeactivity (Figs. 2 and 6C) as compared with a normal
mouse kidney (Fig. 6D). amount of anti-APA mAbs that are able to block the
APA enzyme activity in vitro [10]. In the absence of an
involvement of well-known systemic mediators of in-
DISCUSSION flammation, we found evidence that Ang II mediates the
The interaction of circulating antibodies with intrinsic induction of this acute albuminuria [15]. Several argu-
antigens on podocytes is one of the mechanisms that can ments supported this assumption. The binding of the
lead to immune complex formation in the glomerular injected mAbs to APA blocked the enzyme activity in
capillary wall and can eventually lead to functional and/ vivo. Non-enzyme–inhibiting mAbs never induced an
or morphologic glomerular damage. In the passive HN acute albuminuria. Enalapril and losartan reduced the
injection of antibodies directed against the HN antigenic acute albuminuria by more than 90%. Finally, renal APA
complex, composed of megalin, a 517 kDa glycoprotein mRNA expression, which has been found to correlate
on the cell membranes of podocytes (or gp330) and a with local Ang II levels, was increased after the injection
44 kDa receptor associated protein, leads to the forma- of the mAb [15]. In view of the previously mentioned
tion of subepithelial immune deposits as seen by IF [4, data that multiple domains might be involved in the
5, 16, 28–30]. Recently, multiple nephritogenic domains development of Heymann nephritis (HN), we examined
in the HN antigenic complex have been found that are the effects of the intravenous injection of combinations
involved in the binding of the antibodies and initiation of two anti-APA mAbs. We selected for this study two
of the onset of immune complex formation in this disease enzyme-inhibiting anti-APA mAbs, ASD-3 and ASD-
[4, 30, 31]. Of note, in the Heymann model, the binding 37, both of which are able to induce an albuminuria with
of combinations of mAbs to these nephritogenic domains high doses of mAbs, and one non-enzyme–inhibiting anti-
does not result in proteinuria. During the past two de- APA mAb, ASD-41, which is nonpathogenic even with
cades, other podocytic targets in mice have been investi- very high doses [15]. As demonstrated by the IF-blocking
gated in our laboratory [10, 32–35]. Several years ago, assay and the immunoprecipitation and Western blotting
experiments, the three mAbs used in this study are di-we have described an antibody-mediated model of glo-
Mentzel et al: Induction of albuminuria in mice1344
rected to three different domains on APA, one linear do- lator nitroprusside acutely reduced blood pressure and
proteinuria to a similar extent [39]. By comparing themain (ASD-37) and two discontinuous domains (ASD-3
and ASD-41). The two domains detected by ASD-3 and effects of the two antihypertensives, one with and one
without a renal hemodynamic effect, it was concludedASD-37 are related to the enzyme active site of APA,
as shown by the enzyme activity measurements. Because that the acute reduction of the proteinuria was associated
with a fall in systemic blood pressure and not with alter-there has only been identified one enzymatic site on the
APA molecule, located at the zinc-binding domain, it is ations in renal hemodynamics. We realize, however, that
the b-blocker in the triple therapy may lower basal reninuncertain whether these two mAbs are directed to the
active site itself or to domains surrounding the enzyme levels [40, 41]. Moreover, the drug treatment caused a
firm decrease in blood pressure, which in itself influencesactive site [36–38].
The results of the studies with the injection of the proteinuria [42, 43]. Therefore, a specific role for glomer-
ular Ang II in the induction of albuminuria in this modelcombinations of the anti-APA mAbs including the inter-
vention studies with enalapril/losartan or the triple ther- cannot be excluded. Further studies with mice deficient
for components of the renin-angiotensin system andapy and the measurement of the systemic blood pressure
strongly indicate that another mechanism different from measurements of intrarenal Ang II levels are needed to
assess the role of Ang II.or in addition to the one operating in the single mAb
model is mediating the acute albuminuria. An injection In these experiments, in a mouse model of podocytic
activation we describe a domain-specific induction ofof the combinations ASD-3/37 and ASD-37/41 resulted
in a massive, dose-dependent albuminuria that was much albuminuria after a combined administration of two anti-
APA mAbs. The induction of albuminuria is not depen-higher than and could be induced with much lower doses
than seen with the administration of single mAbs [15]. dent on systemic inflammatory mediators, such as the
complement system, and seems, in contrast to the anti-In contrast, ASD-3/41, which like ASD-37/41 is also di-
rected to an enzyme-related and non-enzyme–related APA model induced by the injection of a single mAb,
not merely related to the inhibition of renal APA enzymedomain, surprisingly had no effect on the glomerular
permeability. activity or the actions Ang II. We hypothesize that bind-
ing to and possibly cross-linking of specific, pathogenicUnlike the findings in the model induced by the injec-
tion of relatively large amounts of single mAbs, the acute domains on APA causes activation of the podocytes.
Like in HN, podocytes may react by the release of media-albuminuria after administration of certain combinations
of mAbs is not merely dependent on an inhibition of the tors that are able to affect the integrity of the glomerular
capillary wall [5, 44–46]. There are several argumentsrenal enzyme activity of APA or the activity of Ang II.
Although some correlation between the amount of albu- that support this hypothesis. First, we found that the
administration of 4 mg of the combinations ASD-3/37min excretion and the extent of inhibition of the APA
enzyme activity could be observed, both ASD-3/37 and and ASD-37/41, which cause proteinuria, resulted in a
more granular binding pattern with aggregation of APAASD-37/41 already induced an albuminuria with doses
that only partially inhibited the enzyme activity. In addi- along the glomerular capillary wall as seen by IF, whereas
an injection of 4 mg of the combination ASD-3/41 ortion, although an injection of 4 mg ASD-3/37 led to an
albuminuria with nearly a complete inhibition of the the single mAbs only induced a more homogenous bind-
ing, with no effect on the normal localization of APA.glomerular enzyme activity, an injection of 4 mg ASD-
37/41 induced an even higher albuminuria with enzyme Further studies with, for example, Fab fragments are
needed to establish a firm relation between the aggrega-activity still present in the glomeruli. Our data of the
blood pressure measurements and intervention studies tion of the formed immune complexes and the induction
of the albuminuria or to demonstrate that this is anwith enalapril/losartan and triple therapy are also not in
favor of a systemic role of Ang II in the induction of the epiphenomenon. Second, another possibility that might
explain the albuminuria is a conformational change ofacute albuminuria. In contrast to the presumed effects of
APA on the renin-angiotensin system and consequently APA brought about by binding of the mAbs to specific
domains, as was described for other cell membrane-asso-on the systemic blood pressure, we found that an injec-
tion of the combinations ASD-3/37 and ASD-37/41 did ciated proteins, such as aminopeptidase N [47, 48]. This
is supported by the finding that the combination ASD-37/not elevate the systemic blood pressure. Treatment with
enalapril and losartan, which supposedly also affects the 41 inhibited the glomerular enzyme activity to a greater
extent than a single anti-APA mAb. Such a conforma-glomerular hemodynamics, reduced the albuminuria by
55%, whereas triple therapy, which has no effect on tional change of APA on the podocytes, possibly in con-
nection with a certain degree of aggregation, might bethe glomerular hemodynamics, also lowered the acute
albuminuria by 82%. Our findings fit with data from the initial event of podocytic activation with a release
of secondary mediators that can affect the integrity ofstudies in humans that revealed that both the ACE-
inhibitor enalaprilat and the non-Ang II–related vasodi- the glomerular capillary wall [1]. An alteration in confor-
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Fig. 6. An enzyme histochemistry on frozen kidney sections of mice at day 1 after injection of 4 mg ASD-3/37 (A), 4 mg ASD-37/41 (B), 4 mg
ASD-3/41 (C), or saline (D). (A) An injection of ASD-3/37 reduced the renal APA enzyme activity considerably. (B) An injection of 4 mg ASD-
37/41 also reduced the APA enzyme activity considerably, but still showed higher enzyme activity than 4 mg ASD-3/37 in A. (C) An injection of
4 mg ASD-3/41 reduced the renal APA enzyme activity only slightly. Activity can be seen in the glomeruli and most brush borders of the proximal
tubular epithelial cells. (D) In the control mouse injected with saline, APA activity is present in the glomeruli and in the brush borders of the
proximal tubular cells (3800).
mation induced by mAbs specific for certain domains phragms in the rat [9]. A single intravenous injection of
this mAb in rats induced an acute proteinuria, reachinghas been reported in a small number of experiments
before, but, until now, not for glomerular proteins in- its peak on day 8 and decreasing to normal levels on day
18. The proteinuria was not dependent on the activationvolved in glomerular damage [47, 48].
The only mAb capable of inducing proteinuria in a of the complement system. The mechanisms of the for-
mation of the immune complexes and the induction ofpassive experimental model is the 5-1-6 mAb, which
appears to recognize a 51 kDa protein of the slit dia- proteinuria in the passive (and probably also active) HN
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tensin II type 1 receptor; FITC, fluorescein isothiocyanate; HN, Hey-are different from the ones operating in the anti-APA
mann nephritis; IF, immunofluorescence; mAb, monoclonal antibody;model after the injection of two anti-APA mAbs. It has PBS, phosphate-buffered saline; PMN, polymorphonuclear granulo-
been found that the passive Heyman’s nephritis antibod- cytes.
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